Ankar Pharma S.L.

Spin-off of CSIC we have the exclusive IP rights to develop Ap-1 for Multiple Sclerosis. 2 Mill€ invested -additional 2 Mill€ to license to a pharma company.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Madrid, Spain
  • Currency EUR
  • Founded 2014
  • Employees 3
  • Incorporation Type LLC
  • Website ankarpharma.com

Company Summary

ANKAR PHARMA es una empresa biotecnológica, constituida como una spin-off del CSIC, con el objetivo de llevar a ensayos clínicos en humanos candidatos a fármacos innovadores centrados en la esclerosis múltiple. Iniciamos la actividad en un proyecto único: el desarrollo de AP-1, una molécula pequeña cuya ventaja fundamental es su triple acción: en modelos preclínicos ha mostrado un importante perfil anti-inflamatorio, una gran capacidad neuroprotectora y además un intenso poder remielinizante (repara el daño neuronal). AP-1 está sólidamente protegido por una patente de producto con fecha de prioridad Octubre de 2009. ANKAR PHARMA tiene una licencia exclusiva de esta patente haciéndose cargo de su desarrollo y su explotación. En la actualidad la patente esta concedida en España y en fases nacionales en Australia, Canadá, Estados Unidos y Europa, donde se espera su concesión inminente.
ANKAR PHARMA está en la Red de Mentores de la Comunidad de Madrid y en la aceleradora de proyectos de la Fundación GAEM (Grupo de afectados por esclerosis múltiple).

Ankar Pharma is a biotechnological start-up that accelerates the pathway from drug discovery to drug market sales , aiming at obtaining successful preclinical trials of drugs for neurodegenerative diseases and sell to pharmaceutical companies the rights to develop the drug into clinical stages and market development. We specialize in neurodegenerative diseases and aspire to license to pharma industry companies the drug at an advanced stage. Our AP-1 molecule for multiple sclerosis has a triple affect which no other actual or potential pipeline drug offers: a triple action that includes reparing damaging neurons.

Team

  • Michael de José Belzunce

  • Ana Martinez
    Chief Research Officer

    Research Professor at the Biological Research Center (CIB) of Spanish National Council for Research (CSIC), having a background formation on Medicinal Chemistry. Focused on drug development for neurodegenerative disorders, spinal cord trauma and multiple sclerosis. Active areas of research involve 2002- 2008, to complete joined NeuroPharma, after named NOSCIRA, as R&D Director. Today in CSIC ,author of >180scientific publications, 30 patents

  • Carmen Gil
    Chief Scientific Officer

    Ph.D. from Complutense University of Madrid in 2001 under the supervision of Prof. A. Martinez.
    After a postdoctoral appointment at Bonn University (Prof. Dr. Stefan Bräse), she joined the Medicinal Chemistry Institute (IQM-CSIC) in 2004 (Staff Scientist) responsible of the design and synthesis of biologically active organic molecules in the neurodegenerative field. Participated in > 30 R&D projects, published > 66 articles, invented 11 patents

  • Stuart Medina Miltimore
    Business Development Officer

    Stuart Medina is an economist and MBA from the Darden School of the University of Virginia. With more than 30 years of professional experience in the biotechnology industry. He has served as financial director and controller in companies such as Kanthal and Genzyme. He has been responsible for investment analysis in UF eBusiness. He was the CEO of ProRetina Therapeutics, a Company developing a therapy for a retinitis pigmentosa.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free